Interestingly, this treatment combined with either sirtinol or olaparib enhanced the sensitivity of the cells against FK866 both in mass cultures and tumorspheres, suggesting that these combinations can be used to reduce the toxic effects of NAMPT inhibition during the incorporation of a more effective therapy.7 Thus, NAMPT inhibitors, in combination with sirtinol or PARP inhibitors, may represent a new therapy for patients with colon cancer. This evidence concerns the gene NAMPT and colonic neoplasm.